Novo Nordisk ((DE:NOVA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
In a recent clinical study update, Novo Nordisk has completed a trial titled ‘A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency.’ The study aimed to evaluate the efficacy and safety of a once-weekly treatment, NNC0195-0092, against a daily growth hormone treatment in children with growth hormone deficiency, highlighting its potential significance in pediatric endocrinology.
The intervention tested in this study was somapacitan, administered as NNC0195-0092, a once-weekly subcutaneous injection. This was compared to the daily administration of Norditropin® FlexPro® pen, aiming to offer a more convenient treatment option for children.
The study was designed as a randomized, double-blind, parallel assignment trial with a primary treatment purpose. Both participants and investigators were masked to ensure unbiased results, with the trial focusing on comparing the two treatment regimens over a 26-week main trial period followed by a 26-week extension.
The study began on March 31, 2016, and was completed with its last update submitted on July 14, 2025. These dates mark the progression from initiation to the latest update, indicating the study’s completion and the availability of data for analysis.
This update could have significant market implications for Novo Nordisk, potentially enhancing its stock performance by demonstrating innovation and leadership in growth hormone treatments. The results may influence investor sentiment positively, especially if the once-weekly treatment proves effective, offering a competitive edge over daily treatments in the industry.
The study is now completed, with further details available on the ClinicalTrials portal.